List of Excipients in Branded Drug ETRAVIRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals	ETRAVIRINE	etravirine	10147-0570	CELLULOSE, MICROCRYSTALLINE
Patriot Pharmaceuticals	ETRAVIRINE	etravirine	10147-0570	CROSCARMELLOSE SODIUM
Patriot Pharmaceuticals	ETRAVIRINE	etravirine	10147-0570	HYPROMELLOSE

Generic Drugs Containing ETRAVIRINE

Company	Ingredient	NDC	Excipient
AvKARE	etravirine	42291-473	CELLULOSE, MICROCRYSTALLINE
AvKARE	etravirine	42291-473	CROSCARMELLOSE SODIUM
AvKARE	etravirine	42291-473	CROSPOVIDONE

What are the Most Frequently-Used Excipients in ETRAVIRINE?

# Of NDCs	Excipient
6	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
6	CROSPOVIDONE

Etravirine Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Etravirine is an oral, poorly water-soluble non-nucleoside reverse transcriptase inhibitor marketed as Intelence. Its commercial formulation opportunity is driven less by new chemical entities and more by bioavailability, dose flexibility, pediatric acceptability, tablet size, taste masking, and lower-cost manufacturing. The strongest excipient strategies are amorphous solid dispersions, wetting and solubilization systems, multiparticulates, and palatable pediatric oral dosage forms.

What is etravirine and which formulation problems matter commercially?

Etravirine is a diarylpyrimidine NNRTI used with other antiretroviral agents for treatment of HIV-1 infection in treatment-experienced patients. Janssen markets Intelence as 25 mg, 100 mg, and 200 mg tablets. The product is administered orally and is labeled for adults and pediatric patients at least two years old who weigh at least 10 kg.[1]

The principal formulation issues are:

Formulation issue	Commercial consequence	Excipient response
Low aqueous solubility	Variable dissolution and absorption	Surfactants, wetting agents, amorphous dispersions, lipid-based systems
High daily tablet burden in some patients	Adherence pressure	Higher-strength tablets, smaller tablets, multiparticulate systems
Need for administration with food	Reduced dosing flexibility	Bioavailability-enhancing formulation and food-effect reduction
Pediatric use	Swallowing and palatability barriers	Dispersible tablets, granules, oral suspensions, taste masking
Long-term HIV treatment	High sensitivity to manufacturing cost	Direct compression, continuous manufacturing, robust excipient supply
Combination therapy	Potential pill burden and compatibility issues	Fixed-dose or co-packaged products, moisture-controlled excipient systems

Etravirine has limited aqueous solubility and belongs to the group of hydrophobic antiretroviral compounds for which particle size, wetting, solid-state form, and dissolution control can materially affect exposure. The approved Intelence label instructs administration following a meal, which creates a commercial opening for formulations that reduce food dependence.[1]

What excipients are used in Intelence tablets?

The approved Intelence tablets contain a conventional solid oral excipient platform. The U.S. label identifies lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate among the inactive ingredients.[1]

Excipient	Likely technical role
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Diluent, dry binder, tablet structure
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow modifier
Magnesium stearate	Lubricant

This composition is commercially important because it indicates that the originator product uses a relatively conventional immediate-release tablet rather than a complex lipid, polymeric, or nanoparticle delivery system. A generic manufacturer can therefore pursue a standard tablet route, while differentiated products can target improved dissolution, dose administration, or pediatric use.

The 25 mg, 100 mg, and 200 mg strengths create an opportunity to optimize tablet weight and manufacturability across a strength matrix. Formulators must manage proportionality carefully because changes in drug loading, lubricant concentration, compression force, and disintegrant level can produce non-linear dissolution behavior.

Which excipient technologies can improve etravirine bioavailability?

Amorphous solid dispersions

Amorphous solid dispersions are the most technically credible platform for increasing apparent solubility. Suitable polymers may include:

• Hypromellose acetate succinate
• Hypromellose
• Polyvinylpyrrolidone
• Copovidone
• Polyethylene oxide
• Methacrylic acid copolymers where pH-triggered release is desired

The formulation objective is to maintain etravirine in a high-energy amorphous state while preventing recrystallization during storage. Polymer selection must account for drug-polymer miscibility, glass-transition temperature, moisture uptake, dissolution supersaturation, and downstream compression performance.

Spray drying is the most direct manufacturing route. Hot-melt extrusion may be feasible if the drug and polymer demonstrate adequate thermal stability. A spray-dried dispersion could support a smaller tablet, lower food dependence, or a lower total excipient burden.

Surfactant and wetting systems

Nonionic surfactants can improve wetting and dissolution. Candidate materials include polysorbates, poloxamers, sodium lauryl sulfate, and lipid-derived surfactants. The main risks are oxidative degradation, peroxide formation, gastrointestinal tolerability, and interaction with packaging.

A small quantity of surfactant may provide a lower-cost alternative to a full amorphous dispersion. The approach is more attractive where the target is dissolution consistency rather than a major increase in exposure.

Lipid-based formulations

Self-emulsifying drug delivery systems and supersaturating lipid systems may address etravirine's hydrophobicity. Potential components include medium-chain triglycerides, mono- and diglycerides, caprylocaproyl macrogolglycerides, and precipitation inhibitors.

Lipid systems are more suitable for softgels, liquid-filled hard capsules, or lipid-adsorbed powders than for conventional compressed tablets. They may reduce food dependence, but physical stability, capsule compatibility, oxidation control, and scale-up can reduce their commercial attractiveness.

Particle engineering

Micronization, nanocrystals, and co-processed particles can increase surface area without introducing a polymeric dispersion. Nanocrystal systems may allow high drug loading and conventional tablet manufacture. Their principal risks are aggregation, Ostwald ripening, surfactant dependence, and dissolution-method sensitivity.

Particle engineering is attractive for a generic manufacturer seeking a differentiated product that avoids extensive polymer screening. It can also support orally disintegrating or dispersible tablets.

What excipient strategy is best for pediatric etravirine?

The pediatric opportunity is stronger for administration technology than for a new adult tablet. Intelence tablets may be dispersed in water for patients unable to swallow tablets, but a purpose-built pediatric dosage form could improve dose accuracy, palatability, and adherence.[1]

Taste masking

Etravirine is likely to require taste masking in a liquid or rapidly dispersing product. Suitable approaches include:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Lipid coating
• Cyclodextrin complexation
• Multiparticulate coating with ethylcellulose or methacrylate polymers
• Flavored granules or sprinkle formulations

Taste masking must not materially delay drug release. A coating that improves palatability but reduces dissolution can create a clinically relevant exposure problem.

Pediatric dosage forms

Commercially relevant formats include:

1. Dispersible tablets for administration in water.
2. Taste-masked granules for sprinkling onto soft food.
3. Sachets containing a unit dose of coated microparticles.
4. Ready-to-use oral suspension.
5. Powder for reconstitution.
6. Orodispersible tablets for older children and adolescents.

A multiparticulate sachet is likely to offer the best balance between stability and administration flexibility. It can accommodate weight-based dosing while avoiding the microbial and preservative burden of an aqueous suspension.

What formulation patents could protect an etravirine product?

A new etravirine product would generally need protection beyond the expired or aging compound patent estate. The most defensible claim categories are:

Solid dispersion patents

Claims may cover:

• Etravirine dispersed in a defined polymer matrix
• Specified drug-to-polymer ratios
• Amorphous-content thresholds
• Spray-drying process parameters
• Dissolution or supersaturation performance
• Stabilizers that prevent recrystallization

Pediatric formulation patents

Potential claims include:

• Taste-masked etravirine particles
• Coated multiparticulates
• Dose units tied to body-weight bands
• Dispersible tablets with defined dispersion time
• Granules compatible with soft food
• Low-pH or neutral-pH oral suspensions

Method-of-use patents

Method claims could target:

• Administration without a meal
• Use in a defined pediatric population
• Reduced pill burden
• Administration through enteral feeding tubes
• Use with specified background antiretroviral regimens

Method-of-use protection is harder to enforce when the formulation does not carry a distinct label limitation. Formulation claims with measurable physical or compositional characteristics generally offer a clearer enforcement position.

Manufacturing patents

Manufacturing claims may cover:

• Spray-drying conditions
• Controlled precipitation
• Nanocrystal production
• Continuous granulation
• Low-shear coating processes
• Moisture-controlled packaging and stabilization

Manufacturing patents are commercially useful when they create a reproducible dissolution profile that competitors cannot easily replicate.

What is the FDA regulatory status and Orange Book position of etravirine?

Intelence is an FDA-approved prescription antiretroviral product. It is regulated as a small-molecule drug rather than a biologic, so biosimilar provisions do not apply.[1,2]

Etravirine products may be submitted through the abbreviated new drug application pathway if the applicant demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug. A reformulated product with a new dosage form, new route, or materially different clinical use may require a 505(b)(2) application rather than a standard ANDA.

The Orange Book remains the relevant source for current reference-listed-drug information, patent certifications, and exclusivity data. FDA's Orange Book identifies approved drug products and, where applicable, listed patents and regulatory exclusivity.[2] Orange Book status can change through patent-listing updates, delistings, pediatric exclusivity, or changes in reference-product designation.

When does etravirine lose exclusivity and what generic entry risks exist?

Etravirine is an older small molecule launched in 2008. The principal compound and early formulation exclusivities are therefore materially aged compared with newer HIV products. Commercial entry risk depends on the remaining enforceable patents, Orange Book listings, pediatric protections, and the economics of manufacturing a low-volume antiretroviral.

Potential generic pathways include:

Entry pathway	Product concept	Primary risk
Conventional ANDA	25 mg, 100 mg, and 200 mg tablets	Price erosion and limited market size
505(b)(2) application	Improved food independence or pediatric dosage form	Clinical and regulatory development cost
Authorized generic or licensed product	Same or substantially similar formulation	Contract and supply-chain dependence
Specialty pediatric product	Granules, sachets, or dispersible tablets	Small addressable patient population
Combination product	Etravirine with other antiretrovirals	Compatibility, clinical, and patent complexity

Paragraph IV litigation risk is generally highest where a generic applicant challenges an unexpired Orange Book-listed formulation or method-of-use patent. The existence, scope, and current enforceability of those patents must be confirmed against the live Orange Book and court dockets before an entry forecast is used in a transaction or investment decision.[2,3]

Which companies are positioned to challenge or commercialize etravirine?

The competitive field includes:

• Generic manufacturers with established antiretroviral tablet capacity
• Contract development and manufacturing organizations with spray-drying or nanocrystal capabilities
• Specialty HIV companies focused on pediatric or salvage-therapy populations
• Companies seeking 505(b)(2) products with improved administration
• Suppliers of functional polymers, surfactants, and taste-masking systems

The commercial opportunity is unlikely to come from a broad first-line HIV product. Current HIV treatment has moved toward integrase inhibitor-based regimens, while etravirine remains associated with treatment-experienced patients and resistance-management strategies.[4] The more defensible market positions are therefore targeted products with clinical or operational value.

How strong is the etravirine patent estate?

The patent estate is strongest when a product combines a protected formulation with a measurable performance advantage. A conventional tablet using the same active ingredient and familiar excipients has limited differentiation potential once core exclusivity expires.

A commercially stronger estate would combine:

1. A composition claim covering a specific amorphous dispersion or coated particle.
2. A process claim covering scalable manufacture.
3. A method claim covering food-independent or pediatric administration.
4. A device, sachet, or enteral-tube administration claim.
5. Data showing improved dissolution, reduced variability, or improved adherence.

Patent strength will depend on claim breadth, prior-art exposure, freedom-to-operate around excipient combinations, and whether the formulation requires a narrow process window. Broad claims to generic polymer classes may face validity pressure. Narrow claims tied to defined solid-state properties or dissolution outcomes may be more defensible but easier to design around.

What licensing and commercial deals are most plausible?

The most likely licensing structures involve formulation technology rather than the etravirine molecule itself. A drug owner could license:

• Spray-dried dispersion technology
• Taste-masked multiparticulate technology
• Pediatric dose-flexibility platform
• Nanocrystal manufacturing
• Global rights to a 505(b)(2) product
• Regional commercialization rights
• Contract manufacturing with supply guarantees

Royalty value would depend on whether the product secures differentiated regulatory labeling. A standard generic tablet typically supports lower royalty economics than a pediatric or food-independent product with clinical data and a longer formulation patent term.

How does etravirine compare with competing HIV drugs?

Attribute	Etravirine	Modern integrase inhibitor products
Drug class	NNRTI	Integrase strand transfer inhibitor
Typical role	Treatment-experienced or resistance-guided therapy	Common first-line and maintenance regimens
Formulation opportunity	Solubility, food dependence, taste masking	Combination stability, long-acting delivery, low-dose tablets
Generic threat	Conventional tablet and 505(b)(2) products	Varies by product and combination patent estate
Pediatric opportunity	Dispersible and weight-band dosing	Often stronger where pediatric formulations are already established
Commercial differentiation	Administration and salvage-therapy utility	Convenience, resistance barrier, and combination simplification

Etravirine should not be evaluated solely against other NNRTIs. Its commercial benchmark is the total HIV regimen, including darunavir, ritonavir or cobicistat, and newer integrase inhibitor combinations. A reformulated etravirine product must deliver a measurable advantage over regimen substitution, not merely an improved tablet profile.

What revenue exposure and generic launch scenarios matter?

Revenue exposure depends on the size of the treatment-experienced population, pricing, payer restrictions, and whether the product is included in combination regimens. The main launch scenarios are:

Standard generic entry

A conventional ANDA product enters after the relevant patent barriers fall or after a successful challenge. This scenario creates rapid price erosion but may be constrained by limited demand and few approved manufacturers.

Authorized generic or partner entry

The originator or a licensee supplies a lower-priced product while retaining manufacturing control. This can moderate external generic penetration.

Differentiated pediatric entry

A company launches a granule, sachet, or dispersible formulation. The addressable market is smaller, but the product may obtain higher net pricing and face fewer direct tablet competitors.

505(b)(2) reformulation

A sponsor develops a food-independent, lower-pill-burden, or enteral-administration product. This scenario requires more evidence but may support a new patent estate and higher commercial value.

Key Takeaways

• Etravirine's main formulation challenge is poor aqueous solubility combined with food-dependent administration.
• The highest-value excipient platforms are amorphous solid dispersions, nanocrystals, surfactant systems, and taste-masked multiparticulates.
• Pediatric sachets and dispersible dosage forms offer greater differentiation than another conventional tablet.
• Intelence uses a conventional tablet excipient system based on lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.[1]
• Etravirine is a small-molecule drug, so biosimilar competition does not apply.
• Generic entry is most likely through an ANDA for conventional tablets or a 505(b)(2) application for a differentiated dosage form.
• A defensible new patent estate should combine composition, process, performance, and administration claims.
• Commercial prospects are concentrated in treatment-experienced HIV, pediatric administration, and regimen-convenience niches rather than broad first-line therapy.

FAQs

Can etravirine be formulated as an oral suspension?

Yes. A suspension is technically feasible, but taste masking, physical stability, dose uniformity, preservative control, and chemical stability would require development. A dry powder or coated multiparticulate product may offer better shelf stability.

Which polymer is most suitable for an etravirine amorphous solid dispersion?

Hypromellose acetate succinate, hypromellose, and copovidone are credible screening candidates. The optimal polymer depends on miscibility, recrystallization control, moisture sensitivity, dissolution performance, and manufacturing process.

Can etravirine be combined with other antiretroviral drugs in one tablet?

Technically, yes, but the commercial and regulatory barriers are substantial. Dose ratios, drug-drug interactions, stability, dissolution, and separate patent estates would need to be addressed.

Is a food-independent etravirine formulation commercially valuable?

Potentially. Removing or reducing meal dependence could improve regimen flexibility, but the product would need comparative pharmacokinetic evidence and a clear advantage over available antiretroviral alternatives.

What packaging is appropriate for an etravirine formulation?

High-barrier blister packaging or bottles with desiccant protection may be appropriate, particularly for moisture-sensitive amorphous dispersions and coated multiparticulates. Packaging selection should follow measured moisture uptake, impurity growth, and dissolution stability.

References

1. Janssen Products, LP. (2023). Intelence (etravirine) tablets: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug product and patent information resources. FDA.

4. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.